La cadena de opciones muestra datos clave de las opciones de acciones de Accolade a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Accolade..

Accolade (NASDAQ:ACCD) Bolsa, Cadena de Opciones

Accolade

Accolade Inc offers technology-enabled solutions that help people understand, navigate, and utilize the healthcare system and their workplace benefits. The company's platform combines open, cloud-based intelligent technology with multimodal support from a team of Accolade Care Advocates and clinicians, including registered nurses, physician medical directors, pharmacists, primary care physicians, and other professionals to provide advocacy, medical opinion, and virtual primary care services.

Accolade Inc

<a href="https://www.bostonfed.org/news-and-events/events/economic-research-conference-series/the-future-of-finance.aspx" title="https://www.bostonfed.org/news-and-events/events/economic-research-conference-series/the-future-of-finance.aspx">https://www.bostonfed.org/news-and-events/events/economic-research-conference-series/the-future-of-finance.aspx</a>

News

Federal Reserve

Fed's Collins To Speak At Federal Reserve Bank of Boston Event At 9AM ET Today

Wolfe Research analyst Alexandria Hammond initiates coverage on Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) with a Underperform rating and announces Price Target of $40.

Price Target

Initiation

Analyst Ratings

MRNA

Wolfe Research Initiates Coverage On Moderna with Underperform Rating, Announces Price Target of $40

Fed's Collins Said Doesn't See Signs of New Price Pressures

Fed's Collins Said Fed Policy Is Restrictive; Expects Lower Rates Will Be Warranted

Wolfe Research analyst Alexandria Hammond initiates coverage on Merck &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) with a Peer Perform rating.

Wolfe Research Initiates Coverage On Merck & Co with Peer Perform Rating

Fed's Collins Said Central Bank to View More Data Before Next Meeting

Boston Fed President Susan Collins Said December Rate Cut Isn't A Done Deal

Wolfe Research analyst Alexandria Hammond initiates coverage on Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) with a Outperform rating and announces Price Target of $1000.

Wolfe Research Initiates Coverage On Eli Lilly with Outperform Rating, Announces Price Target of $1000

A realignment has taken shape in Silicon Valley, with Tesla Inc. CEO Elon Musk&#8216;s support for President-elect Donald Trump encouraging other tech leaders to publicly embrace conservative positions, according to PayPal co-founder Peter Thiel.
What Happened: &#8220;There was some degree to which it was safer for people to speak out when other people were speaking out,&#8221; Thiel said on a podcast on Thursday.
He emphasized that Musk was &#8220;incredibly important&#8221; in this shift, providing what he called &#8220;a great deal of cover&#8221; for other industry figures.
The movement has drawn prominent tech figures into Trump&#8217;s orbit, including venture capitalists Marc Andreessen and David Sacks. On the other end of the spectrum, tech investors and leaders, including Reid Hoffman, Ron Conway, and Mark Cuban, publicly pledged support for Vice President Kamala Harris.
Why It Matters: While Silicon Valley remains predominantly Democratic, Trump gained notable support across the region&#8217;s three main counties, according to voting data analysis <a href="https://www.businessinsider.in/tech/news/silicon-valleys-swing-toward-trump-is-real-heres-the-data-to-prove-it-/articleshow/115231105.cms">by</a> Business Insider.
The industry&#8217;s political transformation reflects growing internal tensions over corporate culture, with Musk&#8217;s political evolution serving as a prominent example. After relocating Tesla&#8217;s headquarters from California to Texas in 2021, Musk described his rightward shift as opposing what he termed the &#8220;<a href="https://www.benzinga.com/news/24/10/41224028/elon-musk-talks-ai-woke-mind-virus-starlink-and-california-governor-gavin-newsom-with-tucker-carlson">woke mind virus</a>.&#8221;
This realignment led to Musk&#8217;s appointment as co-leader of Trump&#8217;s proposed Department of Government Efficiency (DOGE), alongside entrepreneur-turned-politician Vivek Ramaswamy.
Thiel, who backed <a href="https://www.benzinga.com/general/education/24/09/40756735/peter-thiel-supports-trump-backed-ethereums-buterin-5-facts-you-might-not-know-about-paypal-pal">Trump in 2016 but withdrew from political donations this cycle</a>, praised Musk&#8217;s stance as both &#8220;incredibly dangerous&#8221; and &#8220;incredibly courageous.&#8221;
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="Peter Thiel on the Triumph of the Counter-Elites" width="500" height="281" src="https://www.youtube.com/embed/wwJV_NuN43Y?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/global/24/11/41998381/tesla-earnings-will-be-hit-hardest-if-7500-ev-credit-is-cut-warns-gary-black-citing-80-dependence-on-ev-sales-please-do-the-math">Tesla Earnings Will Be Hit Hardest If $7.5K EV Credit Gets Cut By Trump, Warns Gary Black: &#8216;Do The Math&#8217;</a></li>
</ul>
Image via Flickr
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Politics

Markets

Peter Thiel Says Elon Musk's Support For Trump Paved The Way For Other Silicon Valley Leaders To Back Him: 'Incredibly Courageous'

Wolfe Research analyst Alexandria Hammond initiates coverage on Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) with a Outperform rating and announces Price Target of $190.

Wolfe Research Initiates Coverage On Johnson & Johnson with Outperform Rating, Announces Price Target of $190

Wolfe Research analyst Alexandria Hammond initiates coverage on Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) with a Outperform rating and announces Price Target of $110.

GILD

Wolfe Research Initiates Coverage On Gilead Sciences with Outperform Rating, Announces Price Target of $110

General Motors&#8217; (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) <a href="https://www.benzinga.com/news/24/08/40502871/gms-autonomous-driving-unit-cruise-recalls-all-u-s-vehicles-over-concerns-of-unexpected-braking-auto">autonomous driving unit</a> Cruise has agreed to a payment of $500,000 in criminal fines for providing a false record to the National Highway Traffic Safety Administration (NHTSA) regarding a crash in San Francisco involving one of its autonomous vehicles, the Justice Department said on Thursday.
What Happened: Cruise omitted key details of the accident that occurred in San Francisco on Oct. 2, 2023, in its report to the NHTSA, where a robotaxi ran over a pedestrian who was hit by another vehicle and dragged the woman over 20 feet, the department said. 
Cruise admitted to the allegation and agreed to pay the fine, it added.
"Federal laws and regulations are in place to protect public safety on our roads. &nbsp;Companies with self-driving cars that seek to share our roads and crosswalks must be fully truthful in their reports to their regulators," Martha Boersch, Chief of the Office of the U.S. Attorney's Criminal Division, said in a statement. 
Cruise has also agreed to cooperate with government investigations, implement a Safety Compliance Program, and provide annual reports to the U.S. Attorney's Office for three years, failing which it faces prosecution.
Why It Matters: Cruise suspended all of its operations in the U.S. late last year following the&nbsp;<a href="https://www.benzinga.com/news/23/10/35052444/self-driving-cruise-car-accident-leaves-pedestrian-trapped-and-injured-in-san-francisco" target="_blank" rel="noreferrer noopener">accident in San Francisco</a>, leading to heightened regulatory scrutiny and the&nbsp;<a href="https://www.benzinga.com/news/24/05/38606510/us-is-currently-sc-ed-ex-cruise-ceo-calls-for-manufacturing-makeover-to-win-over-chinese-auto-rivals" target="_blank" rel="noreferrer noopener">exit of its co-founder&nbsp;</a>and then CEO&nbsp;Kyle Vogt.
The company&nbsp;<a href="https://www.benzinga.com/news/24/04/38155753/cruise-back-on-phoenix-roads-soon-gms-self-driving-unit-reportedly-gears-up-to-resume-robotaxi-testi" target="_blank" rel="noreferrer noopener">resumed manual driving in the city of Phoenix</a>&nbsp;to gather road information earlier this year in April and in Houston and Dallas, Texas in June.
Cruise&nbsp;is now looking to return to operating driverless vehicles by the end of the year, GM CEO&nbsp;Mary Barra&nbsp;said during the company&#8217;s&nbsp;<a href="https://www.benzinga.com/news/earnings/24/10/41451103/general-motors-surpasses-q3-earnings-and-revenue-estimates" target="_blank" rel="noreferrer noopener">third-quarter earnings call</a> last month.
Cruise&#8217;s Financials: Cruise posted an operating loss of $417 million in the three months through the end of September, lower than the $807 million loss recorded in the corresponding period of last year. GM has spent $583 million on restructuring Cruise this year.
In July, the company also said that it is abandoning its plans to build the Origin autonomous vehicle with no pedals and instead focussing on&nbsp;<a href="https://www.benzinga.com/news/24/07/39903020/gms-cruise-abandons-pedal-less-origin-autonomous-vehicle-pivots-to-next-generation-chevrolet-bolt-in" target="_blank" rel="noreferrer noopener">using its next-generation Chevrolet Bolt&nbsp;</a>for autonomous driving operations.
"This addresses the regulatory uncertainty we faced with the Origin because of its unique design. In addition, per-unit costs will be much lower, which will help Cruise optimize its resources,&#8221; Barra said about the decision then.
Check out more of Benzinga's Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/space/24/11/42000554/spacex-speeds-up-mission-launches-with-a-new-one-taking-off-every-other-day-over-last-month-as-it-races-towards-its-2024-target">SpaceX Speeds Up Mission Launches With A New One Taking Off Every Other Day Over Last Month As It Races Towards Its 2024 Target</a></li>
</ul>
Photo courtesy: GM

Tech

GM's Autonomous Driving Unit Cruise Admits To Falsifying Accident Report To NHTSA, Agrees To Pay $500K Fine

Wolfe Research analyst Alexandria Hammond initiates coverage on Bristol-Myers Squibb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) with a Peer Perform rating.

Wolfe Research Initiates Coverage On Bristol-Myers Squibb with Peer Perform Rating

Wolfe Research analyst Tim Anderson initiates coverage on Amgen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) with a Peer Perform rating.

AMGN

Wolfe Research Initiates Coverage On Amgen with Peer Perform Rating

Wolfe Research analyst Akash Tewari initiates coverage on Biomarin Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) with a Outperform rating and announces Price Target of $95.

BMRN

Wolfe Research Initiates Coverage On Biomarin Pharmaceutical with Outperform Rating, Announces Price Target of $95

Wolfe Research analyst Alexandria Hammond initiates coverage on Biogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) with a Peer Perform rating.

BIIB

Wolfe Research Initiates Coverage On Biogen with Peer Perform Rating

Wolfe Research analyst Alexandria Hammond initiates coverage on AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) with a Outperform rating and announces Price Target of $205.

ABBV

Wolfe Research Initiates Coverage On AbbVie with Outperform Rating, Announces Price Target of $205

Needham analyst Ami Fadia reiterates Blueprint Medicines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>) with a Buy and maintains $135 price target.

Reiteration

BPMC

Needham Reiterates Buy on Blueprint Medicines, Maintains $135 Price Target

Needham analyst Gil Blum reiterates Celcuity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELC#NASDAQ">CELC</a>) with a Buy and maintains $23 price target.

CELC

Needham Reiterates Buy on Celcuity, Maintains $23 Price Target

Needham analyst Ryan Koontz reiterates Gilat Satellite Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILT#NASDAQ">GILT</a>) with a Buy and maintains $8.5 price target.

GILT

Needham Reiterates Buy on Gilat Satellite Networks, Maintains $8.5 Price Target

Here's the major earnings before the open tomorrow

Today, several major companies are expected to report earnings: PepsiCo (PEP) and Accolade (ACCD). Ahead of earnings, TipRanks shows you the expect...

Options Volatility and Implied Earnings Moves Today, October 08, 2024

Accolade GAAP EPS of -$0.30 beats by $0.14, revenue of $106.36M beats by $1.37M

Accolade, Inc. 2025 Q2 - Results - Earnings Call Presentation

Accolade, Inc. (ACCD) Q2 2025 Earnings Call Transcript

Barclays analyst Stephanie Davis maintained a Hold rating on Accolade (ACCD – Research Report) today and set a price target of $5.00. Stephanie Dav...

Accolade (ACCD) Maintains Hold Rating Amid Solid Performance and Cautious Market Outlook

Analysts fell to the sidelines weighing in on PTC Therapeutics (PTCT – Research Report) and Accolade (ACCD – Research Report) with neutral ratings,...

Analysts Offer Insights on Healthcare Companies: PTC Therapeutics (PTCT) and Accolade (ACCD)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Accolade (ACCD – Research Report) and Gilead Scien...

Analysts Offer Insights on Healthcare Companies: Accolade (ACCD) and Gilead Sciences (GILD)

Leerink Partners analyst Michael Cherny has reiterated their bullish stance on ACCD stock, giving a Buy rating yesterday. Michael Cherny has given ...

Accolade's Strong Financial Performance and Positive Future Outlook Justify Buy Rating

In a report released yesterday, Stan Berenshteyn from Wells Fargo maintained a Hold rating on Accolade (ACCD – Research Report), with a price targe...

Accolade Financial Analysis: A Hold Rating Amid Revenue Growth Uncertainties and Operational Challenges

ACCD

PTCT

Legal

Press Releases

Accolade, Inc. (ACCD) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Accolade To Present at Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase

First-of-its-kind Healthcare Innovation Provides Synchronized, Customized Whole-Health Strategies

Accolade To Present at Morgan Stanley 22nd Annual Global Healthcare Conference

Earnings

Accolade to Announce Fiscal Second Quarter 2025 Financial Results

Health Care

Accolade Announces Results for Fiscal Second Quarter 2025

Accolade Welcomes Renalogic to Trusted Partner Ecosystem

Accolade To Present at Upcoming Investor Conferences

Agilon Health

AirSculpt Technologies, Inc. - Common Stock

AirSculpt Technologies

AMN Healthcare Services

American Shared Hospital Services Common Stock

American Shared Hospital

Biodesix

Cryo-Cell International, Inc. Common Stock

Cryo-Cell International

Concord Medical Services Holdings Limited American Depositary Shares (Each represents thirty (30) Class A ordinary shares)

Concord Medical Services

Cross Country Healthcare, Inc. - Common Stock

Cross Country Healthcare

Castle Biosciences

DocGo

Enhabit

Enzo Biochem, Inc. Common Stock ($0.01 Par Value)

Enzo Biochem

Euda Health Holdings Limited - Ordinary Shares

EUDA Health Holdings

Fulgent Genetics

InnovAge Holding

23andMe Holding

ModivCare

National Research Corporation - Common Stock

National Research

Nutex Health

Performant Financial Corporation - Common Stock

Performant Finl

P3 Health Partners Inc. - Class A Common Stock

P3 Health Partners

Prenetics Global Limited - Class A Ordinary Share

Prenetics Global

SBC Medical Group Holdings Incorporated - Common Stock

SBC Medical Group Holding

SHL Telemedicine Ltd - American Depositary Shares

Comments

Accolade

Accolade (ACCD) Opciones

Accolade (NASDAQ:ACCD) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL